Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
Character Biosciences has raised $17.0M in total funding. The most recent round was Series B. The last funding was announced in September 2025.
Character Biosciences's investors include Industry Ventures, Catalio Capital Management, Sanofi Ventures, S32, Cantos.
Character Biosciences is headquartered in Jersey City, United States.
Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.
Character Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Character Biosciences — Funding & Investors." VCBacked, September 17, 2025, https://www.vcbacked.co/company/character-biosciences. Accessed August 14, 2026.
VCBacked. (2025). Character Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/character-biosciences
{{cite web |title=Character Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/character-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated